摘要
肺炎在导致死亡的感染性疾病中居于前列。即使进行充分抗感染及机械通气治疗,重症肺炎患者的预后仍无明显改善。炎症介质的平衡是肺炎结局的关键。肺泡巨噬细胞释放细胞因子和其他炎症介质在重症肺炎发生发展过程中起重要作用,糖皮质激素影响炎症组分的释放而发挥抗炎作用。多年来对糖皮质激素治疗重症肺炎是否有益的研究并未取得确切结果。近年的研究对糖皮质激素治疗重症肺炎有益作用及临床推荐剂量、疗程和减量方案提供了新的依据。
Pneumonia constitutes a major health burden on a global scale and remains a common cause of death in infectious disease. Despite potent anti- infective agents and appropriate mechanical ventilation,no improvements have been found in the prognosis of pneumonia. The balance between inflammatory mediators is key for the outcome of the pulmonary infection and the cytokines and other inflammatory mediators released from alveolar macrophages play an important role in progress of severe pneumonia. Glucocorticoid steroids（ GCs） act on the inflammatory components and have an important role in anti- inflammatory process. Treatments of severe pneumonia with GCs have been developing for years with inconclusive results. Recent studies assess beneficial impact on treatment of severe pneumonia by suggesting specific dosage,period of administration,and tapered dosage.
出处
《天津药学》
2014年第6期45-48,共4页
Tianjin Pharmacy
关键词
糖皮质激素
重症肺炎
细胞因子
glucocorticoid steroids
severe pneumonia
cytokines
